Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · November 06, 2017

2017 Top Stories in Oncology: 1-800-SEND CELLS

Isabel Cunningham MD

 

 Save  Recommend
 Share

Additional Info

  1. PracticeUpdate Editorial Team. FDA Oncology Advisory Committee Recommends Approval of CTL019 for Pediatric, Young Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. PracticeUpdate. 2017. http://www.practiceupdate.com/c/56298/48/1 Accessed November 5, 2017.
  2. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 Results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285-295.
  3. Berdeja JG, Lin Y, Raje NS et al. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. J Clin Oncol. 2017;35(15_Suppl]:3010-3010.
  4. Turtle CJ, Hay KA, Hanfi L, et al. Durable molecular remissions in chronic lymphocytic leukemia treated With CD19-Specific chimeric antigen receptor–modified T cells after failure of Ibrutinib. J Clin Oncol. 2017;35(26) 3010-3020.
  5. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35(31) 3547-3557.

Disclosure statements are available on the authors' profiles:

Isabel Cunningham MD

Further Reading

Most Read This Week

Recently Updated